ALT analyst estimates
Altimmune (ALT) analyst ratings, the average price target and its range, and every firm's latest call.
ALT analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Jun 22, 2026 | Leerink Partners | Altimmune initiated with an Outperform at Leerink | $10.00 |
| Apr 24, 2026 | Goldman Sachs | Altimmune upgraded to Neutral from Sell at Goldman Sachs | $2.50 |
| Jan 27, 2026 | Barclays | Altimmune initiated with an Overweight at Barclays | $20.00 |
| Apr 2, 2024 | H.C. Wainwright | Altimmune (ALT) PT Lowered to $12 at H.C. Wainwright following Q4 report | $12.00 |
| Dec 1, 2022 | Goldman Sachs | Goldman Sachs Initiates Coverage On Altimmune with Buy Rating, Announces Price Target of $20 | $20.00 |
| Nov 11, 2022 | JMP Securities | JMP Securities Maintains Market Outperform on Altimmune, Lowers Price Target to $26 | $26.00 |
| Aug 31, 2022 | Jefferies | Jefferies Maintains Buy on Altimmune, Raises Price Target to $35 | $35.00 |
| Aug 30, 2022 | Piper Sandler | Altimmune management confident on NAFLD Phase 1b study, says Piper Sandler | $25.00 |
| Aug 17, 2022 | H.C. Wainwright | HC Wainwright & Co. Maintains Buy on Altimmune, Raises Price Target to $50 | $50.00 |
- 4 firms rate ALT: 4 buy, 0 hold, 0 sell.
- The average price target is $10.00 from None analysts, from $10.00 to $10.00.
Updated 2026-11-13 04:50 UTC